Lonza Nominates Pharma Veteran Stephen Fry to Board, Strengthening Governance

Lonza Group Ltd, the world's largest contract development and manufacturing organization (CDMO) serving the healthcare industry, has announced a significant board nomination that could reshape its governance and strategic direction. The company, headquartered in Basel, Switzerland with approximately 20,000 employees across five continents, has nominated Stephen Fry as an Independent Member of its Board of Directors. Fry brings an impressive three-decade career at Eli Lilly and Company, where he ultimately served as Executive Vice President and Chief Human Resources Officer for 12 years, leading large-scale organizational transformation and shaping high-performance cultures during periods of significant change. His nomination reflects Lonza's strategic focus on strengthening its governance and people strategy as it continues to generate substantial revenue—CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025—while supporting pharmaceutical and biotech companies in turning breakthrough innovations into viable therapies.

Subject to his election at the Lonza Group Annual General Meeting in May 2026, Fry will also be appointed to both the People and Governance Committee and the Audit and Compliance Committee, positioning him to influence critical aspects of Lonza's operations. Board Chairman Jean-Marc Huet emphasized that Fry's extensive international experience, combined with his strong track record in organizational governance, succession planning, and people strategy development, represents a valuable complementary fit with existing board capabilities. This nomination comes at a time when Lonza, as a global CDMO leader, faces increasing demands for talent retention and organizational excellence in the competitive pharmaceutical manufacturing landscape. Additional materials including Fry's biography and headshot are available for download, providing further insight into his qualifications and background.

The nomination underscores Lonza's commitment to attracting world-leading talent and elevating its high-performing teams to the next level, particularly as the company works alongside pharma and biotech partners to bring life-saving and life-enhancing treatments to patients worldwide. With Fry's deep pharmaceutical industry experience and global leadership perspective, Lonza aims to strengthen its performance culture and governance structures while navigating the complex challenges of the healthcare sector. This strategic move aligns with Lonza's broader mission of combining cutting-edge science, smart technology, and lean manufacturing to support medical innovation. Readers can find more information about the company at www.lonza.com, and the original release is available on www.newmediawire.com, providing comprehensive coverage of this important governance development.